Second-generation  	Second-generation  	 JJ	B-NP
antipsychotic  	antipsychotic  	 JJ	I-NP
long-acting  	long-acting  	 JJ	I-NP
injections 	injections 	 NNS	I-NP
:  	:  	 :	O
systematic  	systematic  	 JJ	B-NP
review  	review  	 NN	I-NP
Second-generation  	Second-generation  	 JJ	I-NP
antipsychotics  	antipsychotics  	 NNS	I-NP
( 	( 	 -LRB-	O
SGAs 	SGAs 	 NNP	B-NP
)  	)  	 -RRB-	O
represent  	represent  	 VBP	O
an  	an  	 DT	O
advance  	advance  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
management  	management  	 NN	O
of  	of  	 IN	O
schizophrenia 	schizophrenia 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
review  	review  	 VB	O
the  	the  	 DT	O
available  	available  	 JJ	O
evidence  	evidence  	 NN	O
concerning  	concerning  	 VBG	B-NP
SGA  	SGA  	 NNP	I-NP
long-acting  	long-acting  	 JJ	I-NP
injections  	injections  	 NNS	I-NP
( 	( 	 -LRB-	O
LAIs 	LAIs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
systematic  	systematic  	 JJ	B-NP
review  	review  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
literature  	literature  	 NN	O
was  	was  	 VBD	O
conducted  	conducted  	 VBN	O
using  	using  	 VBG	O
PubMed 	PubMed 	 JJ	O
.  	.  	 .	O
Risperidone  	Risperidone  	 JJ	B-NP
long-acting  	long-acting  	 JJ	I-NP
injection  	injection  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
first  	first  	 JJ	O
licensed  	licensed  	 JJ	O
SGA-LAI  	SGA-LAI  	 JJ	B-NP
compound  	compound  	 NN	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
management  	management  	 NN	O
of  	of  	 IN	O
schizophrenia 	schizophrenia 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
that  	that  	 DT	O
of  	of  	 IN	O
oral  	oral  	 JJ	B-NP
risperidone 	risperidone 	 NN	I-NP
.  	.  	 .	O
Olanzapine  	Olanzapine  	 JJ	B-NP
pamoate  	pamoate  	 NN	I-NP
has  	has  	 VBZ	O
recently  	recently  	 RB	O
been  	been  	 VBN	O
approved  	approved  	 VBN	O
in  	in  	 IN	O
Europe 	Europe 	 NNP	O
.  	.  	 .	O
In  	In  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
efficacy 	efficacy 	 NN	O
,  	,  	 ,	O
at  	at  	 IN	O
injection  	injection  	 NN	B-NP
intervals  	intervals  	 NNS	I-NP
of  	of  	 IN	O
up  	up  	 RB	O
to  	to  	 TO	O
4  	4  	 CD	O
weeks  	weeks  	 NNS	O
it  	it  	 PRP	O
appears  	appears  	 VBZ	O
comparable  	comparable  	 JJ	O
to  	to  	 TO	O
oral  	oral  	 JJ	B-NP
olanzapine 	olanzapine 	 NN	I-NP
,  	,  	 ,	O
although  	although  	 IN	O
the  	the  	 DT	O
potential  	potential  	 NN	O
for  	for  	 IN	O
; 	; 	 :	O
post-injection  	post-injection  	 JJ	B-NP
syndrome 	syndrome 	 NN	I-NP
'  	'  	 ''	O
( 	( 	 -LRB-	O
delirium 	delirium 	 LS	B-NP
)  	)  	 -RRB-	O
calls  	calls  	 VBZ	O
for  	for  	 IN	O
additional  	additional  	 JJ	O
safety  	safety  	 NN	O
considerations 	considerations 	 NNS	O
.  	.  	 .	O
Paliperidone  	Paliperidone  	 JJ	B-NP
palmitate  	palmitate  	 NN	I-NP
is  	is  	 VBZ	O
currently  	currently  	 RB	O
under  	under  	 IN	O
review  	review  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
licensing  	licensing  	 NN	B-NP
authorities 	authorities 	 NNS	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
also  	also  	 RB	O
affords  	affords  	 VB	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
advantage  	advantage  	 NN	I-NP
of  	of  	 IN	O
monthly  	monthly  	 JJ	O
dosing 	dosing 	 NN	O
.  	.  	 .	O
More  	More  	 RBR	O
long-term  	long-term  	 JJ	O
comparisons  	comparisons  	 NNS	O
of  	of  	 IN	O
SGA-LAIs  	SGA-LAIs  	 JJ	B-NP
with  	with  	 IN	O
oral  	oral  	 JJ	B-NP
SGAs  	SGAs  	 NN	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 RB	O
with  	with  	 IN	O
first-generation  	first-generation  	 JJ	B-NP
antipsychotic  	antipsychotic  	 JJ	I-NP
LAIs  	LAIs  	 NNS	I-NP
are  	are  	 VBP	O
needed 	needed 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
studies  	studies  	 NNS	O
should  	should  	 MD	O
include  	include  	 VB	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
data 	data 	 NNS	I-NP
.  	.  	 .	O
